Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Doctoral Research Award

Direct Payment

$81,000.00

The Potential of the Human Proton Coupled Folate Transporter as a Novel Approach for Therapeutic Targeting of Solid Tumors

EF 2008-09

Résumé
Folates are B vitamins and are essential for life because of their role in DNA synthesis. A cancer cell proliferates in an uncontrolled manner and is highly dependent on DNA synthesis. Antifolates are folate analogs that inhibit the ability of cancer cells to make DNA and replicate, which leads to cancer cell death. Folates and antifolates cannot enter cells on their own and therefore require specific transport proteins. This application for a doctoral research award proposes to better understand the biology and therapeutic potential of the human proton-coupled folate transporter (hPCFT), a major system for collecting folates and antifolates in human tumors and some normal tissues. hPCFT prefers an acidic pH for transport and is directly relevant to cancer therapy as the environment in many tumors tends to be acidic. This, paired with our identification of novel antifolate drugs that are specifically transported by hPCFT but not other major folate transporters provides a means of targeting toxic drugs to tumors, reducing toxic side effects on normal tissues. Proposed studies will determine the therapeutic potential of hPCFT by measuring hPCFT levels and function in tumors compared to normal tissues. In addition, studies will establish relative levels of hPCFT compared to other folate transporters and determine how much hPCFT is required for drug transport and cancer cell killing. Finally, this proposal will seek to determine the therapeutic impact of multiple and redundant folate transport systems on hPCFT-mediated drug accumulation and tumor toxicity. A better understanding of folate transport has implications to human health and disease, relating to folate deficiency and its impact on cardiovascular disease, fetal abnormalities and neurologic disorders. In addition, the development of a new class of tumor-selective cancer drugs as proposed may lead to new therapies and provide new treatment options and less toxicity for cancer patients treated with chemotherapy.
Programme
CIHR Doctoral Research Award
Bénéficiaire
Emplacement
Michigan, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
174628
Name
Kugel Sita
Region
Michigan
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Potential of the Human Proton Coupled Folate Transporter as a Novel Approach for Therapeutic Targeting of Solid Tumors
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$81,000
Cihrequipment2
$0
Programname2
CIHR Doctoral Research Award
Keyworddelim
Antifolates; Chemotherapy; Drug Discovery; Folate; Membrane Transport; Microenvironment; Proton Coupled Folate Transporter; Solid Tumors; Tumor Targeting
Abstract
Folates are B vitamins and are essential for life because of their role in DNA synthesis. A cancer cell proliferates in an uncontrolled manner and is highly dependent on DNA synthesis. Antifolates are folate analogs that inhibit the ability of cancer cells to make DNA and replicate, which leads to cancer cell death. Folates and antifolates cannot enter cells on their own and therefore require specific transport proteins. This application for a doctoral research award proposes to better understand the biology and therapeutic potential of the human proton-coupled folate transporter (hPCFT), a major system for collecting folates and antifolates in human tumors and some normal tissues. hPCFT prefers an acidic pH for transport and is directly relevant to cancer therapy as the environment in many tumors tends to be acidic. This, paired with our identification of novel antifolate drugs that are specifically transported by hPCFT but not other major folate transporters provides a means of targeting toxic drugs to tumors, reducing toxic side effects on normal tissues. Proposed studies will determine the therapeutic potential of hPCFT by measuring hPCFT levels and function in tumors compared to normal tissues. In addition, studies will establish relative levels of hPCFT compared to other folate transporters and determine how much hPCFT is required for drug transport and cancer cell killing. Finally, this proposal will seek to determine the therapeutic impact of multiple and redundant folate transport systems on hPCFT-mediated drug accumulation and tumor toxicity. A better understanding of folate transport has implications to human health and disease, relating to folate deficiency and its impact on cardiovascular disease, fetal abnormalities and neurologic disorders. In addition, the development of a new class of tumor-selective cancer drugs as proposed may lead to new therapies and provide new treatment options and less toxicity for cancer patients treated with chemotherapy.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kugel, Sita
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $81,000~ $0~